Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Avivagen Inc

Healthcare CA VIV

NoneCAD
0.00(0%)

Last update at 2024-07-24T14:02:55.313706Z

Day Range

--
LowHigh

52 Week Range

0.0050.12
LowHigh

Fundamentals

  • Previous Close 0.005
  • Market Cap0.39M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.97439M
  • Revenue TTM0.72M
  • Revenue Per Share TTM0.009
  • Gross Profit TTM 0.40M
  • Diluted EPS TTM-0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Income before tax -6.06621M -6.39416M -4.75129M -4.83642M -4.83406M
Minority interest - - - - -
Net income -6.06621M -6.39416M -4.75129M -4.83642M -4.83406M
Selling general administrative 1.90M 4.69M 4.33M 3.77M 4.27M
Selling and marketing expenses - - - - -
Gross profit 0.40M 0.53M 0.47M 0.53M 0.65M
Reconciled depreciation 0.09M 0.12M 0.13M 0.00464M 0.00254M
Ebit -4.89776M -4.10762M -3.38699M -3.89291M -4.14896M
Ebitda -4.21009M -4.68335M -3.40855M -4.10573M -4.53234M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -1.53370M -4.10762M -3.38699M -3.89291M -4.14896M
Other operating expenses 0.05M 0.17M 0.60M 0.07M 0.07M
Interest expense 1.77M 1.59M 1.22M 0.73M 0.30M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00068M 0.00469M 0.00901M - -
Net interest income -1.16845M -2.24654M -1.33702M -0.89351M -0.43510M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.00000M
Total revenue 0.94M 1.30M 1.18M 0.98M 1.07M
Total operating expenses 2.47M 5.40M 4.56M 4.87M 5.22M
Cost of revenue 0.54M 0.76M 0.71M 0.45M 0.42M
Total other income expense net -3.36406M -0.04000M -0.02728M -0.05000M -0.25000M
Discontinued operations - - - - -
Net income from continuing ops -6.06621M -6.39416M -4.75129M -4.83642M -4.83406M
Net income applicable to common shares -6.06621M -6.39416M -4.75129M -4.83642M -4.83406M
Preferred stock and other adjustments - - - - -
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Total assets 1.37M 3.48M 2.18M 1.89M 3.11M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.03M 0.03M - - -
Total liab 7.35M 7.43M 6.94M 5.14M 3.02M
Total stockholder equity -5.98392M -3.95267M -4.76761M -3.25622M 0.09M
Deferred long term liab - - - - -
Other current liab 0.06M 0.06M 0.03M 0.10M 0.11M
Common stock 34.90M 31.82M 26.56M 23.96M 22.96M
Capital stock 34.90M 31.82M 26.56M 23.96M 22.96M
Retained earnings -45.19453M -40.47301M -35.13670M -31.01270M -26.39573M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.29M 1.41M 0.66M 1.09M 2.21M
Cash and equivalents - - - - -
Total current liabilities 2.10M 6.01M 2.35M 1.30M 1.01M
Current deferred revenue - - - - -
Net debt 5.77M 5.30M 5.20M 3.50M 0.05M
Short term debt - - - 0.65M 0.14M
Short long term debt 0.81M 5.32M 1.36M 0.75M 0.25M
Short long term debt total - - - - -
Other stockholder equity - - - 0.35M 0.25M
Property plant equipment 0.09M 0.26M 0.39M 0.17M 0.07M
Total current assets 1.27M 3.22M 1.78M 1.72M 3.04M
Long term investments - - - - -
Net tangible assets -5.98392M -3.95267M -4.76761M -3.25622M 0.09M
Short term investments - - - - -
Net receivables 0.57M 0.44M 0.61M 0.13M 0.23M
Long term debt 5.25M 1.40M 4.50M 3.84M 2.01M
Inventory 0.31M 1.23M 0.41M 0.45M 0.58M
Accounts payable 0.91M 0.46M 0.71M 0.51M 0.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.17M 0.07M
Deferred long term asset charges - - - - -
Non current assets total 0.09M 0.26M 0.39M 0.17M 0.07M
Capital lease obligations 0.02M 0.09M 0.26M - -
Long term debt total - - - - -
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Investments 0.00000M -0.00871M -0.04430M -0.10920M -0.06954M
Change to liabilities 0.64M -0.22838M 0.23M -0.20637M 0.26M
Total cashflows from investing activities - -0.00871M -0.04430M -0.10920M -0.06954M
Net borrowings -1.12259M -0.85903M 0.69M 2.16M 0.73M
Total cash from financing activities 2.00M 5.35M 2.96M 2.51M 4.48M
Change to operating activities 0.04M -0.03631M -0.05560M 0.13M 0.03M
Net income -6.06621M -6.39416M -4.75129M -4.83642M -4.83406M
Change in cash -1.11783M 0.74M -0.42178M -1.12145M 0.61M
Begin period cash flow 1.41M 0.66M 1.09M 2.21M 1.60M
End period cash flow 0.29M 1.41M 0.66M 1.09M 2.21M
Total cash from operating activities -3.11654M -4.59905M -3.33569M -3.52209M -3.80940M
Issuance of capital stock 4.03M 7.50M 3.00M 1.08M 4.06M
Depreciation 0.09M 0.12M 0.13M 0.00464M 0.00254M
Other cashflows from investing activities - - - - -
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory 0.22M -0.82601M 0.05M -0.01661M -0.48858M
Change to account receivables -0.13432M 0.17M -0.47762M 0.09M -0.12793M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.90734M -1.30124M -0.77446M -0.72599M 0.41M
Change to netincome 2.09M 2.59M 1.54M 1.31M 1.32M
Capital expenditures 0.00000M 0.00871M 0.04M 0.11M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.55M -0.91848M -0.25544M -0.00170M -0.23656M
Stock based compensation 0.15M 0.33M 0.32M 0.32M -
Other non cash items 1.06M 2.12M 1.09M 0.99M 0.69M
Free cash flow -3.11654M -4.60775M -3.37998M -3.63130M -3.87894M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VIV
Avivagen Inc		 - -% - - - 0.54 - 10.64 -2.8012
RX
Biosyent Inc.		 0.05 0.36% 14.00 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 - -% 0.12 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 - -% 0.50 - - 108.48 4.41 140.29 -4.258
LSL
LSL Pharma Group Inc.		 0.005 1.59% 0.32 20.75 - 1.88 1.89 2.85 10.19

Reports Covered

Stock Research & News

View All

Profile

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

Avivagen Inc

100 Sussex Drive, Ottawa, ON, Canada, K1A 0R6

Key Executives

Name Title Year Born
Mr. G. F. Kym Anthony CEO & Director 1956
Dr. Graham Burton Ph.D. Co-Founder, Chief Scientific Officer & Director NA
Dr. James Nickerson Ph.D. Pres and Exec. VP of Bus. Devel. & Product Innovation NA
Mr. Ira Levy Interim Chief Financial Officer NA
Mr. Drew Basek Director of Investor Relations NA
Ms. Tracy Gillett BVSC Director of Companion Animal & Marketing Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.